P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY

Nizar J Bahlis, Christy Samaras, Donna Reece, Michael Sebag, Jeffrey Matous, Jesus Berdeja, Jesse Shustik, Gary Schiller, Siddhartha Ganguly, Kevin Song, Christopher S. Seet, Mirelis Acosta-Rivera, Donald Quick, Bertrand Anz, Gustavo Fonseca, Unicel-Anne Flores, Hongjuan Liu, Christian Gentili, David Siegel

Open source

DOI: 10.1097/01.hs9.0000970432.75766.0c
Published: 8
Container: HemaSphere
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/01.hs9.0000970432.75766.0c,
  title = {P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY},
  author = {Nizar J Bahlis and Christy Samaras and Donna Reece and Michael Sebag and Jeffrey Matous and Jesus Berdeja and Jesse Shustik and Gary Schiller and Siddhartha Ganguly and Kevin Song and Christopher S. Seet and Mirelis Acosta-Rivera and Donald Quick and Bertrand Anz and Gustavo Fonseca and Unicel-Anne Flores and Hongjuan Liu and Christian Gentili and David Siegel},
  year = {2023},
  journal = {HemaSphere},
  doi = {10.1097/01.hs9.0000970432.75766.0c},
  url = {https://doi.org/10.1097/01.hs9.0000970432.75766.0c}
}

RIS

TY  - JOUR
TI  - P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY
AU  - Nizar J Bahlis
AU  - Christy Samaras
AU  - Donna Reece
AU  - Michael Sebag
AU  - Jeffrey Matous
AU  - Jesus Berdeja
AU  - Jesse Shustik
AU  - Gary Schiller
AU  - Siddhartha Ganguly
AU  - Kevin Song
AU  - Christopher S. Seet
AU  - Mirelis Acosta-Rivera
AU  - Donald Quick
AU  - Bertrand Anz
AU  - Gustavo Fonseca
AU  - Unicel-Anne Flores
AU  - Hongjuan Liu
AU  - Christian Gentili
AU  - David Siegel
PY  - 2023
JO  - HemaSphere
DO  - 10.1097/01.hs9.0000970432.75766.0c
UR  - https://doi.org/10.1097/01.hs9.0000970432.75766.0c
ER  -

APA

Bahlis, N. J., Samaras, C., Reece, D., Sebag, M., Matous, J., Berdeja, J., Shustik, J., Schiller, G., Ganguly, S., Song, K., Seet, C. S., Acosta-Rivera, M., Quick, D., Anz, B., Fonseca, G., Flores, U., Liu, H., Gentili, C., & Siegel, D. (2023). P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY. HemaSphere. https://doi.org/10.1097/01.hs9.0000970432.75766.0c

Source records

doaj · retrieved 2026-09-26T11:46:20.868Z